Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.

NCT03229200 is registered in ClinicalTrials.gov with Pharmacyclics Switzerland GmbH as lead sponsor.

NCT NCT03229200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03229200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Lead sponsor
Pharmacyclics Switzerland GmbH
Phase
Phase 4
Overall status
Active, not recruiting
Start date
May 22, 2017
Completion date
May 10, 2027
Enrollment
297 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, leukemia, b-cell, lymphoma, b-cell, lymphoma, non-hodgkin, solid tumor